🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
13/10/2022 1,4100 USD
14/07/2022 1,4100 USD
13/04/2022 1,4100 USD
13/01/2022 1,4100 USD
14/10/2021 1,3000 USD
14/07/2021 1,3000 USD
14/04/2021 1,3000 USD
14/01/2021 1,3000 USD
14/10/2020 1,1800 USD
14/07/2020 1,1800 USD
14/04/2020 1,1800 USD
14/01/2020 1,1800 USD
11/10/2019 1,0700 USD
12/07/2019 1,0700 USD
12/04/2019 1,0700 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/04/2021 109,79 111,44 109,35 110,80 +1,62% 1,90% 6.181.100
20/04/2021 108,12 109,56 108,05 109,03 +0,39% 1,40% 5.411.800
19/04/2021 107,97 108,73 107,12 108,61 +0,65% 1,49% 4.542.900
16/04/2021 107,49 108,55 107,14 107,91 +0,95% 1,31% 8.207.700
15/04/2021 105,99 106,95 105,62 106,89 +0,93% 1,25% 5.730.500
14/04/2021 106,22 106,67 105,58 105,90 -2,14% 1,03% 7.766.700
13/04/2021 108,03 108,36 107,03 108,22 -0,03% 1,23% 6.165.100
12/04/2021 107,82 108,57 107,36 108,25 +0,66% 1,12% 5.647.500
09/04/2021 106,39 107,72 106,05 107,54 +1,36% 1,57% 5.977.500
08/04/2021 105,40 106,92 105,35 106,10 +0,85% 1,49% 5.881.800
07/04/2021 105,53 106,13 104,17 105,21 -0,16% 1,86% 8.037.300
06/04/2021 105,85 106,28 104,88 105,38 -0,72% 1,32% 8.522.500
05/04/2021 109,08 109,08 105,40 106,14 -2,19% 3,37% 10.584.400
01/04/2021 108,92 108,98 107,32 108,52 +0,28% 1,52% 5.091.700
31/03/2021 106,88 109,18 106,80 108,22 +1,34% 2,23% 9.048.000
30/03/2021 106,86 107,03 105,87 106,79 +0,06% 1,09% 5.354.100
29/03/2021 105,76 107,00 105,49 106,73 +0,71% 1,43% 5.472.700
26/03/2021 103,87 106,12 103,84 105,98 +2,02% 2,20% 6.596.900
25/03/2021 102,90 104,15 102,05 103,88 +0,80% 2,04% 6.281.500
24/03/2021 104,82 105,33 103,05 103,06 -1,70% 2,18% 9.420.100
23/03/2021 105,37 105,94 104,51 104,84 -1,00% 1,36% 6.111.600
22/03/2021 103,50 106,40 102,88 105,90 +2,40% 3,40% 7.627.200
19/03/2021 103,93 104,43 102,92 103,42 -0,34% 1,45% 10.899.100
18/03/2021 104,00 104,99 103,42 103,77 -1,21% 1,51% 8.675.100
17/03/2021 103,76 105,09 102,80 105,04 -5,23% 2,21% 19.445.600
16/03/2021 109,95 111,08 109,90 110,84 +0,53% 1,07% 5.570.200
15/03/2021 108,67 110,36 108,36 110,26 +1,89% 1,84% 6.642.200
12/03/2021 107,80 108,58 107,37 108,22 +0,32% 1,12% 5.341.200
11/03/2021 108,13 108,63 107,34 107,87 -0,12% 1,19% 4.671.400
10/03/2021 107,39 108,36 107,05 108,00 +1,13% 1,22% 5.762.600